宏基因组学二代测序技术在重症感染早期抗感染目标性治疗中的一些思考  

Some thoughts on metagenomics next-generation sequencing technology for early anti-infection targeted therapy of severe infections

作　　者：杨翔 邱海波[1] Yang Xiang;Qiu Haibo(Jiangsu Provincial Key Laboratory of Critical Care Medicine,Department of Critical Care Medicine,Zhongda Hospital,School of Medicine,Southeast University,Nanjing 210009,China;Department of Geriatrics,Genernal Hospital of Eastern Theater Command,PLA,Nanjing 210002,China)

机构地区：[1]江苏省重症医学重点实验室、东南大学附属中大医院重症医学科,南京210009 [2]解放军东部战区总医院干部病房一科,南京210002

出　　处：《中华重症医学电子杂志》2022年第4期289-290,共2页Chinese Journal Of Critical Care & Intensive Care Medicine(Electronic Edition)

基　　金：国家自然科学基金重点项目(81930058);江苏省重症医学重点实验室项目(BM2020004);江苏省重点研发计划(社会发展)重点项目--临床前沿技术(BE2019749)。

摘　　要：早期有效、准确的抗生素治疗是降低重症感染患者病死率的关键,准确鉴别病原微生物是恰当的抗生素治疗最重要的前提条件。宏基因组学二代测序技术(mNGS)是一种新型的病原学诊断技术,其具有检测速度快、准确率高、覆盖广泛等特点,近年来已被用于某些特殊病原微生物感染的诊断中。然而,该技术在重症感染早期抗感染目标性治疗中仍存在诸多问题亟待解决。本文总结mNGS在重症领域使用过程中依然面临的几个需要思考的问题。Early effective and accurate antibiotic therapy is the key to reduce mortality of patients with severe infections.Identification of pathogenic microorganism is essential for appropriate antibiotic therapy.Metagenomics next generation sequencing(mNGS)is a novel pathogenic,diagnostic technology with fast detection speed,high accuracy,and comprehensive coverage.mNGS has been used to diagnose specific pathogenic microbial infections in recent years.However,many problems still need to be solved in the early target anti-microbial therapy of severe infections.This paper summarizes several problems that need to be considered in the use of mNGS in severe cases.

关 键 词：宏基因组学二代测序 重症感染 目标性治疗 

分 类 号：R446[医药卫生—诊断学]